Status:
RECRUITING
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Lymphoma
Lymphoma, Hodgkin
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy trea...
Detailed Description
The purpose of this study is to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chem...
Eligibility Criteria
Inclusion
- Ability to understand and the willingness to sign informed consent prior to any study- related procedures.
- Patients diagnosed with lymphoma.
- Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.
- Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
- Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.
- Have physician clearance to participate in exercise.
- Speak English.
- Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.
- Access to a phone that can receive text messages.
Exclusion
- Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.
- Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.
- Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.
- Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.
- Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.
Key Trial Info
Start Date :
June 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06923397
Start Date
June 5 2025
End Date
December 31 2026
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215